November 14, 2022
Gilbert Family Foundation Invests $23 Million Toward Curing Neurofibromatosis with Launch of New Brain Tumor Initiative and Expanded Support for Vision Restoration Initiative
The Gilbert Family Foundation today announced $23 million in grants to fund research projects as part of the organization’s Vision Restoration Initiative (VRI) and Brain Tumor Initiative (BTI).
October 28, 2022
Recently, we brought together nine research teams for our first-ever in-person Gene Therapy Initiative Annual Meeting.
August 4, 2022
Watch: Vision Restoration Initiative Annual Meeting Brings “Dream Team” Together to Advance Therapeutic Research
Our Vision Restoration Initiative (VRI) awardees and their teams convened for our VRI Annual Meeting to discuss the results of their research projects focused on vision restoration therapies. Watch the video to learn more about the event and their findings.
July 18, 2022
The Gilbert Family Foundation is excited to welcome 28 researchers to our 2022 Vision Restoration Initiative (VRI) annual meeting. We will be discussing the latest breakthroughs in neurofibromatosis type 1 (NF1) optic pathway glioma and vision restoration research.
April 28, 2022
Gilbert Family Foundation Furthers Commitment to Curing Neurofibromatosis (NF), Invests Additional $18 Million Toward Gene Therapy Initiative
The Gilbert Family Foundation is excited to announce a new round of three-year grants in the Gene Therapy Initiative to support the development of curative therapies that address the underlying cause of NF1.
October 26, 2021
Preclinical models provide a key role in developing treatments for neurofibromatosis type 1. The Gilbert Family Foundation not only supports projects that utilize available preclinical models, but projects that aim to expand these resources.
September 14, 2021
Gilbert Family Foundation Funds Clinical Study to Understand Vision Loss from NF1 Optic Pathway Glioma
The Gilbert Family Foundation today announced funding of a new $5.4 million clinical study which aims to understand the mechanisms of vision loss caused by NF1-associated optic pathway gliomas, or NF1-OPGs.
July 15, 2021
Gilbert Family Foundation Collaborates with the Children’s Oncology Group and Children’s Hospital of Philadelphia to Validate a New Tool to Measure Progressive Vision Loss
The Gilbert Family Foundation today announced the launch of a clinical study that aims to validate optical coherence tomography (OCT) as a tool to objectively assess the visual system and its response to treatment in NF1 patients with optic pathway gliomas.
May 20, 2021
The Gilbert Family Foundation (GFF) is excited to announce the development of a database for neurofibromatosis type 1 (NF1) research tools in collaboration with Sage Bionetworks. The database aims to support the development of a robust NF1 research toolkit while also lowering the barrier of entry to research for new-to-NF1 […]
December 24, 2020
GFF's Gene Therapy Initiative seeks to explore and develop gene-targeting therapeutic strategies for neurofibromatosis type 1 (NF1) that address the underlying cause of the disease. Targeting the mutated gene itself could yield a more effective, comprehensive response for a greater range of patients.
November 16, 2020
Optic pathway gliomas (OPGs) are slow-growing brain tumors that arise in or around the optic nerve and can cause the degeneration of the optic nerve and retinal ganglion cells (RGCs) leading to vision loss. GFF's Vision Restoration Initiative aims to develop new therapies to protect and restore vision for […]
October 13, 2020
Approximately 1 in 5 patients with neurofibromatosis type 1 (NF1) develop optic pathway gliomas (OPGs). These tumors can cause degeneration of the optic nerve and retinal ganglion cells (RGCs), ultimately leading to vision loss. GFF's Vision Restoration Initiative aims to develop neuroprotection/neuroenhancement therapies that protect and increase performance […]